Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 32,246 shares of the biotechnology company's stock after acquiring an additional 3,312 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.07% of United Therapeutics worth $11,490,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Signaturefd LLC grew its holdings in shares of United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after buying an additional 30 shares in the last quarter. Parallel Advisors LLC increased its holdings in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after buying an additional 30 shares during the last quarter. Great Lakes Advisors LLC raised its position in United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after acquiring an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its stake in United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after acquiring an additional 33 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after acquiring an additional 39 shares during the period. Institutional investors own 94.08% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on UTHR. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Trading Up 1.8 %

UTHR traded up $5.38 during trading on Wednesday, reaching $312.26. 461,017 shares of the company's stock were exchanged, compared to its average volume of 450,237. The firm has a fifty day moving average price of $336.64 and a two-hundred day moving average price of $355.09. The stock has a market capitalization of $14.02 billion, a PE ratio of 13.71, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a one year low of $227.75 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the prior year, the firm posted $4.36 earnings per share. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock worth $26,134,500 over the last three months. 11.90% of the stock is owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.